Distinguished in Dowling-Meara Epidermolysis Bullosa Simplex

Dr. Amy S. Paller

Pediatrics | Dermatology
Lurie Children's Medical Group Inc.
1131 N Techny Rd, 
Northbrook, IL 
Clinical Trials:Currently Recruiting for 2 Trials
Distinguished in Dowling-Meara Epidermolysis Bullosa Simplex
Lurie Children's Medical Group Inc.
1131 N Techny Rd, 
Northbrook, IL 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Amy Paller is a Pediatrics specialist and a Dermatologist in Northbrook, Illinois. Mrs. Paller and is rated as a Distinguished provider by MediFind in the treatment of Dowling-Meara Epidermolysis Bullosa Simplex. Her top areas of expertise are Atopic Dermatitis, Nonbullous Congenital Ichthyosiform Erythroderma, Netherton Syndrome, Congenital Hemidysplasia with Ichthyosiform Erythroderma and Limbs Defects, and Gastrostomy.

Her clinical research consists of co-authoring 444 peer reviewed articles and participating in 18 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 5 articles and participated in 1 clinical trial in the study of Dowling-Meara Epidermolysis Bullosa Simplex.

Specialties
Pediatrics
Dermatology
Licenses
Pediatrics in IL
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Ambetter
  • EPO
  • HMO
  • PPO
AmeriHealth
  • EPO
  • HMO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California

Accepted plan types not found. Please verify directly with the provider.

CareSource
  • HMO
Cigna
  • EPO
  • HMO
  • PPO
Elixir

Accepted plan types not found. Please verify directly with the provider.

Health Alliance
  • EPO
  • HMO
  • POS
  • PPO
Health Care Services Corporation

Accepted plan types not found. Please verify directly with the provider.

Highmark
  • EPO
  • HMO
  • PPO
Horizon Healthcare
  • EPO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independence
  • EPO
  • HMO
  • POS
  • PPO
Johns Hopkins Healthcare

Accepted plan types not found. Please verify directly with the provider.

MDwise

Accepted plan types not found. Please verify directly with the provider.

Medicaid

Accepted plan types not found. Please verify directly with the provider.

Medimpact Healthcare Systems

Accepted plan types not found. Please verify directly with the provider.

Meridian Choice

Accepted plan types not found. Please verify directly with the provider.

Molina

Accepted plan types not found. Please verify directly with the provider.

Northern Plains Alliance

Accepted plan types not found. Please verify directly with the provider.

Oscar
  • EPO
  • HMO
  • PPO
Trustmark

Accepted plan types not found. Please verify directly with the provider.

WellCare Health Plans

Accepted plan types not found. Please verify directly with the provider.

View 20 Less Insurance Carriers -

Locations

LURIE CHILDREN'S MEDICAL GROUP INC.
1131 N Techny Rd, Northbrook, IL 60062
Other Locations
LURIE CHILDREN'S MEDICAL GROUP INC.
225 E Chicago Ave, Box 118, Chicago, IL 60611

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

18 Clinical Trials

Observational Study of Pediatric Rheumatic Diseases: The CARRA Registry
Observational Study of Pediatric Rheumatic Diseases: The CARRA Registry
Enrollment Status: Recruiting
Publish Date: November 07, 2024
Systems Biology of Early Atopy
Systems Biology of Early Atopy
Enrollment Status: Recruiting
Publish Date: April 24, 2024
A Long-term Study to Assess the Safety and Efficacy of Lebrikizumab in Patients With Moderate-to-Severe Atopic Dermatitis (ADjoin)
A Long-term Study to Assess the Safety and Efficacy of Lebrikizumab in Patients With Moderate-to-Severe Atopic Dermatitis (ADjoin)
Enrollment Status: Active_not_recruiting
Publish Date: February 27, 2025
Intervention Type: Biological
Study Drug: Lebrikizumab
Study Phase: Phase 3
An Open-Label and Long-Term Extension Study to Evaluate the Efficacy and Safety of Ustekinumab in the Treatment of Patients With Ichthyoses.
An Open-Label and Long-Term Extension Study to Evaluate the Efficacy and Safety of Ustekinumab in the Treatment of Patients With Ichthyoses.
Enrollment Status: Completed
Publish Date: February 12, 2025
Intervention Type: Drug
Study Drug: Ustekinumab
Study Phase: Early Phase 1
Characterization of Lipoprotein Composition and Function in Pediatric Psoriasis Before and After Treatment
Characterization of Lipoprotein Composition and Function in Pediatric Psoriasis Before and After Treatment
Enrollment Status: Active_not_recruiting
Publish Date: January 30, 2025
Intervention Type: Other
Open Label Treatment of Beremagene Geperpavec (B-VEC)
Open Label Treatment of Beremagene Geperpavec (B-VEC)
Enrollment Status: Completed
Publish Date: April 09, 2024
Intervention Type: Biological
Study Drug: Open Label Topical Beremagene Geperpavec (B-VEC)
Study Phase: Phase 3
An Open-Label, Single-Arm Study to Assess the Safety and Efficacy of Lebrikizumab in Adolescent Patients With Moderate-to-Severe Atopic Dermatitis
An Open-Label, Single-Arm Study to Assess the Safety and Efficacy of Lebrikizumab in Adolescent Patients With Moderate-to-Severe Atopic Dermatitis
Enrollment Status: Completed
Publish Date: February 24, 2023
Intervention Type: Biological
Study Drug: Lebrikizumab
Study Phase: Phase 3
A Phase III Efficacy and Safety Study of Beremagene Geperpavec (B-VEC, Previously KB103) for the Treatment of Dystrophic Epidermolysis Bullosa (DEB)
A Phase III Efficacy and Safety Study of Beremagene Geperpavec (B-VEC, Previously KB103) for the Treatment of Dystrophic Epidermolysis Bullosa (DEB)
Enrollment Status: Completed
Publish Date: February 17, 2023
Intervention Type: Biological, Other
Study Drug: Topical Beremagene Geperpavec
Study Phase: Phase 3
A Randomized,Single-Blind, Placebo-controlled, Self-matched Pairing, Independent Evaluated Study to Evaluate the Efficacy and Safety of RGN-137 Topical Gel in Subjects With Junctional and Dystrophic Epidermolysis Bullosa (CELEB)
A Randomized,Single-Blind, Placebo-controlled, Self-matched Pairing, Independent Evaluated Study to Evaluate the Efficacy and Safety of RGN-137 Topical Gel in Subjects With Junctional and Dystrophic Epidermolysis Bullosa (CELEB)
Enrollment Status: Terminated
Publish Date: August 22, 2022
Intervention Type: Drug
Study Drug: RGN-137
Study Phase: Phase 2
A Smart, Always -On Health Monitoring System, Sub-Study: No Strings Attached: Wireless Sensor Technology in the Prentice NICU
A Smart, Always -On Health Monitoring System, Sub-Study: No Strings Attached: Wireless Sensor Technology in the Prentice NICU
Enrollment Status: Completed
Publish Date: June 14, 2022
Intervention Type: Device
Genetic Analysis of Pediatric Psoriasis
Genetic Analysis of Pediatric Psoriasis
Enrollment Status: Completed
Publish Date: April 20, 2022
Intervention Type: Other
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Pivotal Study to Evaluate the Safety and Efficacy of VP-102 Topical Film-Forming Solution [0.7% (w/v) Cantharidin] in Subjects (2 Years and Older) With Molluscum Contagiosum
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Pivotal Study to Evaluate the Safety and Efficacy of VP-102 Topical Film-Forming Solution [0.7% (w/v) Cantharidin] in Subjects (2 Years and Older) With Molluscum Contagiosum
Enrollment Status: Completed
Publish Date: December 14, 2021
Intervention Type: Combination product
Study Phase: Phase 3
Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate Safety, Tolerability, and Efficacy of Ixekizumab in Patients From 6 to Less Than 18 Years of Age With Moderate-to-Severe Plaque Psoriasis
Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate Safety, Tolerability, and Efficacy of Ixekizumab in Patients From 6 to Less Than 18 Years of Age With Moderate-to-Severe Plaque Psoriasis
Enrollment Status: Completed
Publish Date: September 27, 2021
Intervention Type: Drug
Study Phase: Phase 3
An Open-Label, Pilot Pharmacokinetic Study of Ruxolitinib Phosphate Cream in Pediatric Subjects With Atopic Dermatitis
An Open-Label, Pilot Pharmacokinetic Study of Ruxolitinib Phosphate Cream in Pediatric Subjects With Atopic Dermatitis
Enrollment Status: Completed
Publish Date: November 10, 2020
Intervention Type: Drug
Study Phase: Phase 1
AAD-PEPR: Asthma and Atopic Dermatitis Validation of PROMIS Pediatric Instruments Sub-Study: Clinically Relevant Endpoints in Atopic Dermatitis in Children (CREAD-C)--Funded by Regeneron
AAD-PEPR: Asthma and Atopic Dermatitis Validation of PROMIS Pediatric Instruments Sub-Study: Clinically Relevant Endpoints in Atopic Dermatitis in Children (CREAD-C)--Funded by Regeneron
Enrollment Status: Completed
Publish Date: October 09, 2020
Intervention Type: Other
Study Phase: Not Applicable
Pre-SunBeam Pilot Study: Comparative Assessment of TEWL Measurements From AquaFlux vs. Handheld GPSkin Pro in Young Children With and Without AD
Pre-SunBeam Pilot Study: Comparative Assessment of TEWL Measurements From AquaFlux vs. Handheld GPSkin Pro in Young Children With and Without AD
Enrollment Status: Completed
Publish Date: September 07, 2020
Intervention Type: Device
Study Phase: Not Applicable
A Phase 3, Multi-center, Randomized, Double-Blind, Placebo Controlled Study of the Efficacy and Safety of SD-101 Cream in Patients With Epidermolysis Bullosa
A Phase 3, Multi-center, Randomized, Double-Blind, Placebo Controlled Study of the Efficacy and Safety of SD-101 Cream in Patients With Epidermolysis Bullosa
Enrollment Status: Completed
Publish Date: April 09, 2020
Intervention Type: Drug
Study Phase: Phase 3
An International, Multicenter, Randomized, Double-Blind, Parallel-Group Phase 2 Study Evaluating the Safety and Efficacy of Diacerein 1% Ointment Topical Formulation in Subjects With Epidermolysis Bullosa Simplex
An International, Multicenter, Randomized, Double-Blind, Parallel-Group Phase 2 Study Evaluating the Safety and Efficacy of Diacerein 1% Ointment Topical Formulation in Subjects With Epidermolysis Bullosa Simplex
Enrollment Status: Terminated
Publish Date: November 05, 2019
Intervention Type: Drug
Study Phase: Phase 2
View 16 Less Clinical Trials

444 Total Publications

A "boring" worm? New World screwworm neuromyiasis in a patient with Darier disease.
A "boring" worm? New World screwworm neuromyiasis in a patient with Darier disease.
Journal: JAAD case reports
Published: April 16, 2025
Similar Doctors
Experienced in Dowling-Meara Epidermolysis Bullosa Simplex
Dr. Leah E. Lalor
Dermatology
Experienced in Dowling-Meara Epidermolysis Bullosa Simplex
Dr. Leah E. Lalor
Dermatology
3223 S 103rd St, 
Milwaukee, WI 
 (61.4 mi)
414-328-5800
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Leah Lalor is a Dermatologist in Milwaukee, Wisconsin. Dr. Lalor and is rated as an Experienced provider by MediFind in the treatment of Dowling-Meara Epidermolysis Bullosa Simplex. Her top areas of expertise are Cafe-Au-Lait Spots, Legius Syndrome, Dowling-Meara Epidermolysis Bullosa Simplex, and Dominant Dystrophic Epidermolysis Bullosa. Dr. Lalor is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mrs. Paller's expertise for a condition
ConditionClose
View All 9 Elite Conditions
View All 15 Distinguished Conditions
View All 37 Advanced Conditions
View All 41 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile